Search

Your search keyword '"Punt, C."' showing total 691 results
Start Over Author "Punt, C."
691 results on '"Punt, C."'

204. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)

Author

Punt, C. J., primary, Tol, J., additional, Rodenburg, C. J., additional, Cats, A., additional, Creemers, G., additional, Schrama, J. G., additional, Erdkamp, F. L., additional, Vos, A., additional, Mol, L., additional, and Antonini, N. F., additional

Published
2008
Full Text
View/download PDF

207. Partial characterization of protein tyrosine kinases in human lymphoid cells

Author

Punt, C. J., Rijksen, G., van Oirschot, B. A., Kester-Schipper, G. P., van der Heijden, M. C., Dekker, A. W., Staal, G. E., and Other departments

Subjects
animal structures
Abstract

We have examined several aspects of protein tyrosine kinase (PTK)-activity in the cytosolic and membrane fractions of both normal and malignant lymphoid cells. The expression of the PTK-encoding oncogenes fes, abl and src, was investigated with the use of antibodies generated to their respective gene products. These antibodies recognized proteins in all cell types examined, most frequently in both the cytosolic and the membrane fraction. PTKs were partially characterized by FPLC. PTK-activities of column fractions were assayed using a non-radioactive dot blot assay. Cytosolic and membrane fractions showed FPLC patterns with a constant as well as a variable part in both normal and malignant cells, suggestive of PTKs with specialized functions in normal cell growth and transformation. Lastly, using antibodies to phosphotyrosine, we found that cytosolic fractions contained the majority of proteins phosphorylated at tyrosine in all cell types. Normal peripheral blood lymphocytes and B-lymphoma cells showed a great similarity in tyrosine phosphorylation pattern, while in tonsillar lymphocytes a clearly different pattern was found. These methods further characterize PTK-activities in lymphoid cells, and the results give evidence that PTKs in normal and malignant cells have both similar and different aspects

Published
1992

208. Fluorouracil continuous infusion plus alfa interferon plus oral folinic acid in advanced colorectal cancer

Author

Punt, C. J., de Mulder, P. H., Burghouts, J. T., Wagener, D. J., and Other departments

Abstract

Several reports on fluorouracil (5-FU) and alfa interferon (IFN-alpha) combination therapy in patients with advanced colorectal cancer have been published. In our study high-dose continuous infusion 5-FU (60 mg/kg per 48 hours), oral folinic acid (FA) (8 x 90 mg during 5-FU), and IFN-alpha three times weekly were combined. Because the addition of IFN-alpha has not been tested before, and serious toxicity of 5-FU plus IFN-alpha therapy has been reported, the IFN-alpha dose was escalated from 3 to 10 million units (MU)/dose in the first 11 patients. Grade 3 toxicity was noted in four patients, and consisted mainly of oral mucositis. No grade 4 toxicity occurred. Three partial responses were noted. Preliminary results of a phase II study, in which all patients received IFN-alpha at 10 MU/dose, show grade 3 and 4 toxicities in 24% and 4% of patients, respectively. This compares favorably with other trials in which 5-FU and IFN-alpha was used without FA

Published
1992

212. Sequential compared to combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC): A Dutch Colorectal Cancer Group (DCCG) phase III study

Author

Punt, C. J., primary, Koopman, M., additional, Douma, J., additional, Wals, J., additional, Honkoop, A. H., additional, Erdkamp, F. L., additional, de Jong, R. S., additional, Rodenburg, C. J., additional, Mol, L., additional, and Antonini, N. F., additional

Published
2007
Full Text
View/download PDF

219. Water and polymer dynamics in a model polysaccharide hydrogel: the role of hydrophobic/hydrophilic balance.

Author

Rossi, B., Venuti, V., D'Amico, F., Gessini, A., Castiglione, F., Mele, A., Punt, C., Melone, L., Crupi, V., Majolino, D., Trotta, F., and Masciovecchio, C.

Abstract

The molecular dynamics of water and a polymer matrix is here explored in a paradigmatic model of a polysaccharide hydrogel, by the combined use of UV Raman scattering and infrared measurements. The case example of cyclodextrin nanosponges (CDNS)/hydrogel is chosen since the simultaneous presence in the structure of the polymer matrix of both hydrophilic and hydrophobic sites mimics the complexity of polysaccharide hydrogels. In this way, the contributions provided by the balance between the hydrophilicity/hydrophobicity and the grade of entanglement of the polymer hydrogel to lead to the formation of the gel phase are separately accounted and evaluated. As main results, we found that the hydrophobic CH groups inserted on the aromatic ring of CDNS experience a more pronounced dynamic perturbation with respect to the carbonyl groups due to the collision between the solvent and vibrating atoms of the polymer. The overall results provide a detailed molecular picture of the swelling phenomena occurring when a chemically cross-linked polymer contacts with water or biological fluids and exploits the potentiality of UV Raman spectroscopy to retrieve dynamic information besides their structural counterpart obtained by the classical analysis of the basic features of vibrational spectra. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

227. 25 Update of EORTC melanoma trials. Final results of the EORTC melanoma group trials: EORTC 18951 in stage IV and EORTC 18952 in stage IIB–III

Author

Eggermont, A. M. M., primary, Suciu, S., additional, Ruka, W., additional, Gore, M., additional, Testori, A., additional, Kruit, W., additional, Punt, C. J. A., additional, Stoitchkov, K., additional, Schadendorf, D., additional, Spatz, A., additional, Ruiter, D., additional, Lienard, D., additional, and Keilholz, U., additional

Published
2004
Full Text
View/download PDF

230. Huidtumoren.

Author

van Rossum, M. M., Pasch, M. C., Punt, C. J. A., and Gerritsen, M. J. P.

Abstract

Copyright of Het Oncologie Formularium is the property of Springer eBooks and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2010
Full Text
View/download PDF

234. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of the novel anticancer agent E7070 in four phase I studies

Author

Van Kesteren, CH., primary, Mathôt, R. A. A., additional, Raymond, E., additional, Armand, J. P., additional, Dittrich, CH., additional, Dumez, H., additional, Roché, H., additional, Droz, J. P., additional, Punt, C., additional, Ravic, M., additional, Wanders, J., additional, Beijnen, J. H., additional, Fumoleau, P., additional, and Schellens, J. H. M., additional

Published
2002
Full Text
View/download PDF

242. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR

Author

de Vries, T J, primary, Fourkour, A, additional, Punt, C J A, additional, Locht, L T F van de, additional, Wobbes, T, additional, Bosch, S van den, additional, Rooij, M J M de, additional, Mensink, E J B M, additional, Ruiter, D J, additional, and Muijen, G N P van, additional

Published
1999
Full Text
View/download PDF

245. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

Author

Keilholz, U, primary, Conradt, C, additional, Legha, S S, additional, Khayat, D, additional, Scheibenbogen, C, additional, Thatcher, N, additional, Goey, S H, additional, Gore, M, additional, Dorval, T, additional, Hancock, B, additional, Punt, C J, additional, Dummer, R, additional, Avril, M F, additional, Bröcker, E B, additional, Benhammouda, A, additional, Eggermont, A M, additional, and Pritsch, M, additional

Published
1998
Full Text
View/download PDF

247. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.

Author

Keilholz, U, primary, Goey, S H, additional, Punt, C J, additional, Proebstle, T M, additional, Salzmann, R, additional, Scheibenbogen, C, additional, Schadendorf, D, additional, Liénard, D, additional, Enk, A, additional, Dummer, R, additional, Hantich, B, additional, Geueke, A M, additional, and Eggermont, A M, additional

Published
1997
Full Text
View/download PDF

249. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004).

Author

Ruers, T., Punt, C., Van Coevorden, F., Pierie, J. P. E. N., Borel-Rinkes, I., Ledermann, J. A., Poston, G., Bechstein, W., Lentz, M. A., Mauer, M., Van Cutsem, E., Lutz, M. P., and Nordlinger, B.

Subjects
*CATHETER ablation, *COLON cancer treatment, *METASTASIS, *CLINICAL trials, *LIVER cancer, *COMBINED modality therapy, *CANCER invasiveness
Abstract

Background This study investigates the possible benefits of radiofrequency ablation (RFA) in patients with non-resectable colorectal liver metastases. Methods This phase II study, originally started as a phase III design, randomly assigned 119 patients with non-resectable colorectal liver metastases between systemic treatment (n = 59) or systemic treatment plus RFA ( ± resection) (n = 60). Primary objective was a 30-month overall survival (OS) rate >38% for the combined treatment group. Results The primary end point was met, 30-month OS rate was 61.7% [95% confidence interval (CI) 48.2–73.9] for combined treatment. However, 30-month OS for systemic treatment was 57.6% (95% CI 44.1–70.4), higher than anticipated. Median OS was 45.3 for combined treatment and 40.5 months for systemic treatment (P = 0.22). PFS rate at 3 years for combined treatment was 27.6% compared with 10.6% for systemic treatment only (hazard ratio = 0.63, 95% CI 0.42–0.95, P = 0.025). Median progression-free survival (PFS) was 16.8 months (95% CI 11.7–22.1) and 9.9 months (95% CI 9.3–13.7), respectively. Conclusions This is the first randomized study on the efficacy of RFA. The study met the primary end point on 30-month OS; however, the results in the control arm were in the same range. RFA plus systemic treatment resulted in significant longer PFS. At present, the ultimate effect of RFA on OS remains uncertain. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results